Publications by authors named "Corinne Carpenter"
Purpose: Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital setting. This study aimed to evaluate safety and health care resource utilization (HRU) in real-world patients with multiple myeloma who initiated teclistamab SUD in an outpatient setting.
View Article and Find Full Text PDFBackground: To describe outcomes of high-risk patients with coronavirus disease 2019 (COVID-19) treated with sotrovimab, other monoclonal antibodies (mAbs), or antivirals, and patients who did not receive early COVID-19 treatment. We also evaluate the comparative effectiveness of sotrovimab versus no treatment in preventing severe clinical outcomes.
Methods: This observational retrospective cohort study analyzed Mayo Clinic electronic health records.
Background: Early diagnosis of pulmonary hypertension (PH) is critical for effective treatment and management. We aimed to develop and externally validate an artificial intelligence algorithm that could serve as a PH screening tool, based on analysis of a standard 12-lead ECG.
Methods: The PH Early Detection Algorithm (PH-EDA) is a convolutional neural network developed using retrospective ECG voltage-time data, with patients classified as "PH-likely" or "PH-unlikely" (controls) based on right heart catheterisation or echocardiography.
Article Synopsis
- The study compares the administration times of daratumumab (DARA) for multiple myeloma, highlighting that the subcutaneous (DARA SC) formulation takes significantly less time (3-5 min) compared to the intravenous (DARA IV) formulation (3-7 hours).
- Data were gathered from electronic health records of patients at Mayo Clinic who received DARA between April 2017 and October 2021, analyzing patient experiences with both administration methods.
- Results showed that DARA SC led to 2.7-3.0 hours shorter clinic times and reduced incidences of administration-related reactions, suggesting efficiency and resource-saving benefits of the subcutaneous method.
Background: As the coronavirus disease 2019 (COVID-19) vaccination campaign unfolds, it is important to continuously assess the real-world safety of Food and Drug Administration (FDA)-authorized vaccines. Curation of large-scale electronic health records (EHRs) enables near-real-time safety evaluations that were not previously possible.
Methods: In this retrospective study, we deployed deep neural networks over a large EHR system to automatically curate the adverse effects mentioned by physicians in over 1.